Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2023

Open Access 01-12-2023 | NSCLC | Review

Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review

Authors: Mohammad Saleh Sadeghi, Mohadeseh lotfi, Narges Soltani, Elahe Farmani, Jaime Humberto Ortiz Fernandez, Sheida Akhlaghitehrani, Safaa Hallol Mohammed, Saman Yasamineh, Hesam Ghafouri Kalajahi, Omid Gholizadeh

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

Carcinoma of the lung is among the most common types of cancer globally. Concerning its histology, it is categorized as a non-small cell carcinoma (NSCLC) and a small cell cancer (SCLC) subtype. MicroRNAs (miRNAs) are a member of non-coding RNA whose nucleotides range from 19 to 25. They are known to be critical regulators of cancer via epigenetic control of oncogenes expression and by regulating tumor suppressor genes. miRNAs have an essential function in a tumorous microenvironment via modulating cancer cell growth, metastasis, angiogenesis, metabolism, and apoptosis. Moreover, a wide range of information produced via several investigations indicates their tumor-suppressing, oncogenic, diagnostic assessment, and predictive marker functions in different types of lung malignancy. miRNA mimics or anti-miRNAs can be transferred into a lung cancer cell, with possible curative implications. As a result, miRNAs hold promise as targets for lung cancer treatment and detection. In this study, we investigate the different functions of various miRNAs in different types of lung malignancy, which have been achieved in recent years that show the lung cancer-associated regulation of miRNAs expression, concerning their function in lung cancer beginning, development, and resistance to chemotherapy, also the probability to utilize miRNAs as predictive biomarkers for therapy reaction.

Graphical abstract

Literature
1.
Yuan M, et al. Signal pathways and precision therapy of small-cell Lung cancer. Signal Transduct Target Therapy. 2022;7(1):1–18.
2.
3.
Tammemägi MC, et al. USPSTF2013 versus PLCOm2012 Lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. Lancet Oncol. 2022;23(1):138–48.PubMedPubMedCentralCrossRef
4.
Dwivedi K, et al. An explainable AI-driven biomarker discovery framework for Non-small Cell Lung Cancer classification. Comput Biol Med. 2023;153:106544.PubMedCrossRef
5.
Thandra KC, et al. Epidemiology of Lung cancer. Contemp Oncology/Współczesna Onkologia. 2021;25(1):45–52.PubMedCrossRef
6.
7.
Rudin CM, et al. Small-cell Lung cancer. Nat Reviews Disease Primers. 2021;7(1):1–20.
8.
Krist AH, et al. Screening for Lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962–70.PubMedCrossRef
9.
Hui Z, et al. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell Lung cancer (NSCLC). Cell Death Dis. 2022;13(7):1–18.CrossRef
10.
Black RC, Khurshid H. NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance. RI Med J. 2015;98(10):25–8.
11.
Shames DS, Wistuba II. The evolving genomic classification of Lung cancer. J Pathol. 2014;232(2):121–33.PubMedCrossRef
12.
Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR exon 20 insertions in non–small cell Lung Cancer: recent advances and clinical UpdatesTargeting EGFR exon 20 insertions in NSCLC. Cancer Discov. 2021;11(9):2145–57.PubMedPubMedCentralCrossRef
13.
Lim TKH, et al. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer. 2023;184:107293.PubMedCrossRef
14.
Martín-Sánchez JC, et al. Projections in breast and Lung cancer mortality among women: a bayesian analysis of 52 countries worldwide. Cancer Res. 2018;78(15):4436–42.PubMedCrossRef
15.
Weiss G, et al. EGFR regulation by microRNA in Lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008;19(6):1053–9.PubMedCrossRef
16.
Yang C, et al. LncRNA PCAT6 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition of lung adenocarcinoma cell by targeting miR-545-3p. Mol Biol Rep. 2023;50(4):3557–68.PubMedPubMedCentralCrossRef
17.
Kaźmierczak D, et al. Elevated expression of mir-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell Lung cancer. Translational Lung Cancer Research. 2022;11(5):722.PubMedPubMedCentralCrossRef
18.
Lai Y, et al. Mir-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Biochem Biophys Res Commun. 2019;511(2):260–5.PubMedCrossRef
19.
Gao HX et al. miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1 Molecular medicine reports, 2016. 14(5): p. 4135–43.
20.
Yan C, et al. MiR-760 suppresses non-small cell Lung cancer proliferation and Metastasis by targeting ROS1. Environ Sci Pollut Res. 2018;25:18385–91.CrossRef
21.
Ma Z, et al. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell Lung cancer A549 cells. Acta Biochim Biophys Sin. 2015;47(8):630–8.PubMedCrossRef
22.
Jin H, et al. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell Lung cancer progression. J Experimental Clin Cancer Res. 2019;38:1–11.CrossRef
23.
24.
Fan Q, et al. MiR-193a-3p is an important tumour suppressor in Lung cancer and directly targets KRAS. Cell Physiol Biochem. 2017;44(4):1311–24.PubMedCrossRef
25.
Spitschak A, et al. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit. Mol Cancer. 2017;16(1):1–16.CrossRef
26.
Lasithiotaki I, et al. Aberrant expression of miR-21, miR-376c and miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell Lung cancer. Oncotarget. 2017;8(68):112371–83.PubMedCrossRef
27.
Cui J, et al. HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell Lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism. J Translational Med. 2023;21(1):1–16.CrossRef
28.
Bogatyrova O, et al. FGFR1 overexpression in non-small cell Lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. Eur J Cancer. 2021;151:136–49.PubMedCrossRef
29.
Huang Q, et al. miR–497 inhibits the proliferation and migration of A549 non–small–cell Lung cancer cells by targeting FGFR1. Mol Med Rep. 2019;20(4):3959–67.PubMed
30.
31.
Sun Z, Zhang T, Chen B. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes proliferation and Metastasis of osteosarcoma cells by targeting c-met and SOX4 via miR-34a/c-5p and miR-449a/b. Med Sci Monitor: Int Med J Experimental Clin Res. 2019;25:1410.CrossRef
32.
Li Y, et al. MiR-182 inhibits the epithelial to mesenchymal transition and Metastasis of Lung cancer cells by targeting the Met gene. Mol Carcinog. 2018;57(1):125–36.PubMedCrossRef
33.
Chen Q-y, et al. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget. 2016;7(17):24510.PubMedPubMedCentralCrossRef
34.
Boren T, et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 2008;110(2):206–15.PubMedCrossRef
35.
Ye L, et al. Exosomes-regulated lipid metabolism in tumorigenesis and cancer progression: a comprehensive review. Cytokine & Growth Factor Reviews; 2023.
36.
Zhu Q, et al. MiR-124-3p impedes the Metastasis of non-small cell Lung cancer via extracellular exosome transport and intracellular PI3K/AKT signaling. Biomark Res. 2023;11(1):1.PubMedPubMedCentralCrossRef
37.
Wang Z, et al. MiR-142-5p suppresses tumorigenesis by targeting PIK3CA in non-small cell Lung cancer. Cell Physiol Biochem. 2017;43(6):2505–15.PubMedCrossRef
38.
Meng F, Zhang L. Mir-183-5p functions as a Tumor suppressor in Lung cancer through PIK3CA inhibition. Exp Cell Res. 2019;374(2):315–22.PubMedCrossRef
39.
Yu Sh, et al. miR-99a suppresses the Metastasis of human non‐small cell Lung cancer cells by targeting AKT1 signaling pathway. J Cell Biochem. 2015;116(2):268–76.PubMedCrossRef
40.
Yoo J, et al. The novel miR-9500 regulates the proliferation and migration of human Lung cancer cells by targeting Akt1. Cell Death & Differentiation. 2014;21(7):1150–9.CrossRef
41.
Liu C, et al. microRNA-548l is involved in the migration and invasion of non-small cell Lung cancer by targeting the AKT1 signaling pathway. J Cancer Res Clin Oncol. 2015;141:431–41.PubMedCrossRef
42.
Cao L, et al. GAS5 knockdown reduces the chemo-sensitivity of non-small cell Lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis. Biomed Pharmacother. 2017;93:570–9.PubMedCrossRef
43.
44.
Gong J, et al. MicroRNA–20a promotes non–small cell Lung cancer proliferation by upregulating PD–L1 by targeting PTEN. Oncol Lett. 2022;23(5):1–8.CrossRef
45.
Ortiz GGR, et al. A state-of-the-art review on the MicroRNAs roles in hematopoietic stem cell aging and longevity. Cell Communication and Signaling. 2023;21(1):1–16.CrossRef
46.
Meng X, et al. The roles of different microRNAs in the regulation of cholesterol in viral hepatitis. Cell Communication and Signaling. 2023;21(1):1–13.
47.
Norouzi M, et al. Recent advances on nanomaterials-based fluorimetric approaches for microRNAs detection. Mater Sci Engineering: C. 2019;104:110007.CrossRef
48.
49.
Sargazi S et al. Opportunities and challenges of using high-sensitivity nanobiosensors to detect long noncoding RNAs: a preliminary review. Int J Biol Macromol, 2022.
50.
Gholizadeh O et al. Recent advances in treatment Crimean–Congo hemorrhagic fever virus: A concise overview Microbial Pathogenesis, 2022: p. 105657.
51.
52.
Yasamineh S et al. A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. Int J Pharm, 2022: p. 121878.
53.
Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends in Genetics; 2022.
54.
55.
Pereira DM, et al. Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2013;18(5–6):282–9.PubMedCrossRef
56.
Calin GA, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic Leukemia. Proc Natl Acad Sci. 2002;99(24):15524–9.PubMedPubMedCentralCrossRef
57.
Takamizawa J, et al. Reduced expression of the let-7 microRNAs in human Lung Cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753–6.PubMedCrossRef
58.
59.
Zhong S, et al. miRNAs in Lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in Lung cancer. Translational Res. 2021;230:164–96.CrossRef
60.
61.
He Q, et al. Analysis of differential expression profile of miRNA in peripheral blood of patients with Lung cancer. J Clin Lab Anal. 2019;33(9):e23003.PubMedPubMedCentralCrossRef
62.
63.
64.
O’Brien J, et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.CrossRef
65.
Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview MicroRNA Profiling, 2017: p. 1–10.
66.
Leitão AL, Enguita FJ. A structural view of miRNA Biogenesis and function. Volume 8. Non-coding RNA; 2022. p. 10. 1.
67.
Pietrykowska H, et al. Biogenesis, conservation and function of miRNA in liverworts. Journal of Experimental Botany; 2022.
68.
Berindan-Neagoe I, et al. MicroRNAome genome: a treasure for cancer diagnosis and therapy. Cancer J Clin. 2014;64(5):311–36.CrossRef
69.
Denli AM, et al. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231–5.PubMedCrossRef
70.
71.
72.
73.
Zhao L et al. The Role of miRNA in Ovarian Cancer: an Overview Reproductive Sciences, 2022: p. 1–8.
74.
Wu Z-H, et al. miRNA biomarkers for predicting overall survival outcomes for head and neck squamous cell carcinoma. Genomics. 2021;113(1):135–41.PubMedCrossRef
75.
76.
Bravo-Vázquez LA et al. Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives. Front Bioeng Biotechnol, 2023. 11.
77.
Susanti R, Dafip M, Mustikaningtyas D. OncomiR structure and network prediction on Adenomatosis Polyposis Coli (APC) gene silencing regulation in Colorectal Cancer. Trends in Sciences. 2023;20(10):6168–8.CrossRef
78.
Mardani R, et al. MicroRNA in Leukemia: Tumor suppressors and oncogenes with prognostic potential. J Cell Physiol. 2019;234(6):8465–86.PubMedCrossRef
79.
Izzotti A, et al. Relationship between the miRNA profiles and oncogene mutations in non-smoker Lung cancer. Relevance for Lung cancer personalized screenings and treatments. J Personalized Med. 2021;11(3):182.CrossRef
80.
Ferrante M, Cristaldi A, Oliveri G, Conti. Oncogenic role of miRNA in environmental exposure to plasticizers: a systematic review. J Personalized Med. 2021;11(6):500.CrossRef
81.
82.
83.
84.
Xiong Q, et al. miR-133b targets NCAPH to promote β-catenin degradation and reduce cancer stem cell maintenance in non-small cell Lung cancer. Signal Transduct Target Therapy. 2021;6(1):1–3.
85.
Kim DH, et al. Exosomal miR-1260b derived from non-small cell Lung cancer promotes Tumor Metastasis through the inhibition of HIPK2. Volume 12. Cell death & disease; 2021. pp. 1–10. 8.
86.
Zou P, et al. Mir-192-5p suppresses the progression of Lung cancer bone Metastasis by targeting TRIM44. Sci Rep. 2019;9(1):1–9.CrossRef
87.
Iqbal MA et al. MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance Molecular aspects of medicine, 2019. 70: p. 3–20.
88.
Feng B, et al. Non-small-cell Lung cancer and miRNAs: novel biomarkers and promising tools for treatment. Clin Sci (Lond). 2015;128(10):619–34.PubMedCrossRef
89.
Calin GA et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers Proceedings of the National Academy of Sciences, 2004. 101(9): p. 2999–3004.
90.
Heller G, et al. Genome-wide miRNA expression profiling identifies mir-9-3 and miR-193a as targets for DNA methylation in non–small cell lung CancersmiRNA methylation in NSCLCs. Clin Cancer Res. 2012;18(6):1619–29.PubMedCrossRef
91.
Wang Z, et al. DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell Lung cancer. Cancer Biol Ther. 2011;11(5):490–6.PubMedCrossRef
92.
Chin LJ, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non–small cell Lung cancer risk. Cancer Res. 2008;68(20):8535–40.PubMedPubMedCentralCrossRef
93.
O’Donnell KA, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435(7043):839–43.PubMedCrossRef
94.
95.
96.
Mohamed A, et al. Altered glutamine metabolism and therapeutic opportunities for Lung cancer. Clin Lung Cancer. 2014;15(1):7–15.PubMedCrossRef
97.
Quirico L, et al. miRNA-guided reprogramming of glucose and glutamine metabolism and its impact on cell adhesion/migration during solid Tumor progression. Cell Mol Life Sci. 2022;79(4):216.PubMedPubMedCentralCrossRef
98.
Fang R, et al. miR-143 regulates cancer glycolysis via targeting hexokinase 2. J Biol Chem. 2012;M112:jbc.
99.
Liu M, et al. Downregulating microRNA-144 mediates a metabolic shift in Lung cancer cells by regulating GLUT1 expression. Oncol Lett. 2016;11(6):3772–6.PubMedPubMedCentralCrossRef
100.
Zhao X, et al. MicroRNA-124 suppresses proliferation and glycolysis in non-small cell Lung cancer cells by targeting AKT-GLUT1/HKII. Tumour Biol. 2017;39(5):1010428317706215.PubMedCrossRef
101.
102.
Puissegur M, et al. miR-210 is overexpressed in late stages of Lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011;18(3):465.PubMedCrossRef
103.
104.
Quesnelle DC, Bendena WG, Chin-Sang ID. A compilation of the diverse miRNA functions in Caenorhabditis elegans and Drosophila melanogaster Development. Int J Mol Sci. 2023;24(8):6963.PubMedPubMedCentralCrossRef
105.
Pop-Bica C, et al. The clinical utility of miR-21 and let-7 in non-small cell Lung cancer (NSCLC). A systematic review and meta-analysis. Front Oncol. 2020;10:516850.PubMedPubMedCentralCrossRef
106.
Bica-Pop C, et al. Overview upon miR-21 in Lung cancer: focus on NSCLC. Cell Mol Life Sci. 2018;75:3539–51.PubMedCrossRef
107.
108.
Yang C, et al. The MiR-17-92 gene cluster is a blood-based marker for cancer detection in non-small-cell Lung cancer. Am J Med Sci. 2020;360(3):248–60.PubMedPubMedCentralCrossRef
109.
Zhao W et al. The miR-17-92 cluster: Yin and Yang in human cancers. Cancer Treat Res Commun, 2022: p. 100647.
110.
Zhang Y, et al. Detection of circulating exosomal mir-17-5p serves as a novel non-invasive diagnostic marker for non-small cell Lung cancer patients. Pathology-Research and Practice. 2019;215(8):152466.PubMedCrossRef
111.
112.
113.
Xu H, et al. MiR-31 functions as a Tumor suppressor in Lung Adenocarcinoma mainly by Targeting HuR. Clin Lab. 2016;62(4):711–8.PubMed
114.
115.
116.
Yang X, et al. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant Breast cancer cells by targeting FN1. Discov Med. 2017;24(131):75–85.PubMed
117.
Sharma A, et al. Exploring the role of miR-200 family in regulating CX3CR1 and CXCR1 in lung adenocarcinoma Tumor microenvironment: implications for therapeutic intervention. Sci Rep. 2023;13(1):16333.PubMedPubMedCentralCrossRef
118.
119.
Zhang J, et al. miR-101 represses Lung cancer by inhibiting interaction of fibroblasts and cancer cells by down-regulating CXCL12. Volume 74. Biomedicine & Pharmacotherapy; 2015. pp. 215–21.
120.
Zhang X, et al. MiR-101-3p inhibits the growth and Metastasis of non-small cell Lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1. Volume 93. Biomedicine & Pharmacotherapy; 2017. pp. 1065–73.
121.
122.
Li P, et al. Upregulated miR-106a plays an oncogenic role in Pancreatic cancer. FEBS Lett. 2014;588(5):705–12.PubMedCrossRef
123.
Xie X, et al. miR-106a promotes growth and Metastasis of non-small cell Lung cancer by targeting PTEN. Int J Clin Exp Pathol. 2015;8(4):3827.PubMedPubMedCentral
124.
Guo S, et al. Inhibition mechanism of Lung cancer cell Metastasis through targeted regulation of Smad3 by miR–15a. Oncol Lett. 2020;19(2):1516–22.PubMed
125.
126.
Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential Tumor suppressor and therapeutic candidate in cancer. J Experimental Clin Cancer Res. 2019;38(1):1–13.CrossRef
127.
Daugaard I, et al. The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma. Exp Mol Pathol. 2017;102(3):484–91.PubMedCrossRef
128.
Tanaka N, et al. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell Lung cancer. Lung Cancer. 2012;76(1):32–8.PubMedCrossRef
129.
Mizuno K, et al. The microRNA expression signature of small cell Lung cancer: Tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes. J Hum Genet. 2017;62(7):671–8.PubMedCrossRef
130.
Li S et al. The Value of Serum Exosomal miR-184 in the Diagnosis of NSCLC 2022. 2022: p. 9713218.
131.
Rao X, Lu Y. C1QTNF6 Targeted by MiR-184 Regulates the Proliferation, Migration, and Invasion of Lung Adenocarcinoma Cells Molecular Biotechnology, 2022. 64(11): p. 1279–1287.
132.
Lin T-C, et al. MicroRNA-184 deregulated by the MicroRNA-21 promotes Tumor malignancy and poor outcomes in non-small cell Lung cancer via targeting CDC25A and c-Myc. Ann Surg Oncol. 2015;22:1532–9.CrossRef
133.
134.
Foss KM, et al. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell Lung cancer. J Thorac Oncol. 2011;6(3):482–8.PubMedCrossRef
135.
Donzelli J, et al. Small extracellular vesicle-derived miR‐574‐5p regulates PGE2‐biosynthesis via TLR7/8 in Lung cancer. J Extracell Vesicles. 2021;10(12):12143.PubMedPubMedCentralCrossRef
136.
Huang W et al. The Regulatory Mechanism of miR-574-5p Expression in Cancer 2022. 13(1).
137.
Ho CS, Noor SM, Nagoor NH. MiR-378 and MiR-1827 regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, respectively. J Cancer. 2018;9(2):331–45.PubMedPubMedCentralCrossRef
138.
Fan G, Xu P, Tu P. MiR-1827 functions as a Tumor suppressor in lung adenocarcinoma by targeting MYC and FAM83F. J Cell Biochem. 2020;121(2):1675–89.PubMedCrossRef
139.
140.
Kunz M, et al. MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumor Biology. 2017;39(7):1010428317706430.PubMedCrossRef
141.
142.
Hashemi ZS, et al. Lung cancer and miRNAs: a possible remedy for anti-metastatic, therapeutic and diagnostic applications. Expert Rev Respir Med. 2017;11(2):147–57.PubMedCrossRef
143.
Zhao Z, et al. MicroRNA-25 regulates small cell Lung cancer cell development and cell cycle through cyclin E2. Int J Clin Exp Pathol. 2014;7(11):7726–34.PubMedPubMedCentral
144.
Miko E, et al. miR-126 inhibits proliferation of small cell Lung cancer cells by targeting SLC7A5. FEBS Lett. 2011;585(8):1191–6.PubMedCrossRef
145.
Ye L, et al. MiR-130 exerts Tumor suppressive function on the tumorigenesis of human non-small cell Lung cancer by targeting PTEN. Am J Transl Res. 2017;9(4):1856–65.PubMedPubMedCentral
146.
Hou L, et al. Critical role of miR-155/FoxO1/ROS axis in the regulation of non-small cell lung carcinomas. Tumour Biol. 2016;37(4):5185–92.PubMedCrossRef
147.
Huang P, et al. MicroRNA-181 functions as a Tumor suppressor in non-small cell Lung cancer (NSCLC) by targeting Bcl-2. Tumour Biol. 2015;36(5):3381–7.PubMedCrossRef
148.
Kumar S, et al. Analysis of miR-375-3p, miR-197-3p, and miR-15a-5p expression and their clinical relevance as biomarkers in Lung cancer. Technol Cancer Res Treat. 2022;21:15330338221080981.PubMedPubMedCentralCrossRef
149.
Sp N, et al. Mechanistic insights of anti-immune evasion by nobiletin through regulating miR-197/STAT3/PD-L1 signaling in non-small cell Lung cancer (NSCLC) cells. Int J Mol Sci. 2021;22(18):9843.PubMedPubMedCentralCrossRef
150.
Liu Y, et al. microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell Lung cancer. Oncol Rep. 2016;36(6):3529–35.PubMedCrossRef
151.
Zhou R, et al. Tumor invasion and Metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell Lung cancer. Oncotarget. 2015;6(42):44609–22.PubMedPubMedCentralCrossRef
152.
Zhang Z, et al. Antitumor activity of anti-miR‐21 delivered through lipid nanoparticles. Adv Healthc Mater. 2023;12(6):2202412.CrossRef
153.
Zhang X et al. Downregulated miR-18a and miR-92a synergistically suppress non-small cell lung cancer via targeting Sprouty 4 Bioengineered, 2022. 13(4): p. 11281–11295.
154.
155.
Zhu W, et al. miR-31/QKI‐5 axis facilitates cell cycle progression of non‐small‐cell Lung cancer cells by interacting and regulating p21 and CDK4/6 expressions. Cancer Med. 2023;12(4):4590–604.PubMedCrossRef
156.
Zhang Y, Yang Q, Wang S. MicroRNAs: a new key in Lung cancer. Cancer Chemother Pharmacol. 2014;74(6):1105–11.PubMedCrossRef
157.
Yu F, et al. Hypoxic tumor-derived exosomal mir-31-5p promotes lung adenocarcinoma Metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling. J Experimental Clin Cancer Res. 2021;40(1):1–15.CrossRef
158.
Zhu C, et al. Mir-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis. Strahlenther Onkol. 2022;198(3):304–14.PubMedCrossRef
159.
Cavallari I, et al. The miR-200 family of microRNAs: fine tuners of epithelial-mesenchymal transition and circulating cancer biomarkers. Cancers. 2021;13(23):5874.PubMedPubMedCentralCrossRef
160.
Garinet S, et al. Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. Br J Cancer. 2021;125(11):1544–51.PubMedPubMedCentralCrossRef
161.
Xue B, et al. miR-200 deficiency promotes Lung cancer Metastasis by activating notch signaling in cancer-associated fibroblasts. Genes Dev. 2021;35(15–16):1109–22.PubMedPubMedCentralCrossRef
162.
Liu C, et al. Roles of miR-200 family members in Lung cancer: more than Tumor suppressors. Future Oncol. 2018;14(27):2875–86.PubMedCrossRef
163.
Kundu ST, et al. The miR-200 family and the miR-183 ~ 96 ~ 182 cluster target Foxf2 to inhibit invasion and Metastasis in Lung Cancers. Oncogene. 2016;35(2):173–86.PubMedCrossRef
164.
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other Diseases. Nat Rev Drug Discov. 2017;16(3):203–22.PubMedCrossRef
165.
Gan H, Xu X, Bai Y. Trametes robiniophila represses angiogenesis and Tumor growth of Lung cancer via strengthening let-7d-5p and targeting NAP1L1. Bioengineered. 2022;13(3):6698–710.PubMedPubMedCentralCrossRef
166.
Xie P, et al. Sequential serum Let-7 is a Novel Biomarker to Predict Accelerated Reproliferation during Fractional Radiotherapy in Lung Cancer. Clin Lung Cancer. 2016;17(5):e95–e101.PubMedCrossRef
167.
Pulliero A, et al. Let-7a downregulation accompanied by KRAS Mutation is Predictive of Lung Cancer Onset in cigarette smoke–exposed mice. Int J Mol Sci. 2023;24(14):11778.PubMedPubMedCentralCrossRef
168.
Izzotti A, et al. Early and late effects of aspirin and naproxen on microRNAs in the lung and blood of mice, either unexposed or exposed to cigarette smoke. Oncotarget. 2017;8(49):85716.PubMedPubMedCentralCrossRef
169.
Yin J, et al. let–7 and miR–17 promote self–renewal and drive gefitinib resistance in non–small cell Lung cancer. Oncol Rep. 2019;42(2):495–508.PubMedPubMedCentral
170.
Shahverdi M, et al. Knockdown of myeloid cell Leukemia-1 by MicroRNA-101 increases sensitivity of A549 Lung Cancer cells to Etoposide. Iran J Med Sci. 2021;46(4):298–307.PubMedPubMedCentral
171.
Chen Q et al. miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6 OncoTargets and therapy, 2019. 12: p. 835.
172.
Meng X, et al. miR–101–3p sensitizes lung adenocarcinoma cells to irradiation via targeting BIRC5. Oncol Lett. 2021;21(4):1–1.CrossRef
173.
Han L, et al. MiR-101 inhibits the proliferation and Metastasis of Lung cancer by targeting zinc finger E-box binding homeobox 1. Am J Translational Res. 2018;10(4):1172.
174.
Guo X, et al. Cancer-associated fibroblasts promote migration and invasion of non-small cell Lung cancer cells via mir-101-3p mediated VEGFA secretion and AKT/eNOS pathway. Front Cell Dev Biology. 2021;9:3491.CrossRef
175.
Han L, et al. MicroRNA-106a regulates autophagy-related cell death and EMT by targeting TP53INP1 in Lung cancer with bone Metastasis. Cell Death Dis. 2021;12(11):1037.PubMedPubMedCentralCrossRef
176.
Chen CQ, et al. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16 – 1 via HDAC3 in non-small cell Lung cancer. Mol Cell Biochem. 2013;383(1–2):137–48.PubMedCrossRef
177.
Arfan A, Andarini SL. The role of miRNA in Non-small Cell Lung Carcinoma. Respiratory Sci. 2022;2(3):165–74.CrossRef
178.
Wang H, et al. Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via targeting the FGF2 gene. Pharmacogenomics and Personalized Medicine. 2021;14:497.PubMedPubMedCentralCrossRef
179.
van Zandwijk N, et al. MesomiR 1: a phase I study of TargomiRs in patients with refractory malignant pleural Mesothelioma (MPM) and Lung cancer (NSCLC). Ann Oncol. 2015;26:ii16.CrossRef
180.
181.
Sun D, et al. Distinct roles of miR-34 family members on suppression of lung squamous cell carcinoma. Biomed Pharmacother. 2021;142:111967.PubMedCrossRef
182.
Pandey M et al. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2021. 1876(1): p. 188552.
183.
184.
Sun Y, et al. miR–574–5p mediates epithelial–mesenchymal transition in small cell Lung cancer by targeting vimentin via a competitive endogenous RNA network. Oncol Lett. 2021;21(6):1–9.CrossRef
185.
San Ho C, Noor SM, Nagoor NH. MiR-378 and MiR-1827 regulate Tumor Invasion, Migration and Angiogenesis in Human Lung Adenocarcinoma by Targeting RBX1 and CRKL, respectively. J Cancer. 2018;9(2):331.CrossRef
186.
Guo X, et al. The inhibitory effect of microRNA-1827 on anoikis resistance in lung adenocarcinoma A549 cells via targeting caveolin-1. Acta Biochim Biophys Sin. 2020;52(10):1148–55.PubMedCrossRef
187.
188.
Stahlhut C, Slack FJ. Combinatorial action of MicroRNAs let-7 and miR-34 effectively synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle. 2015;14(13):2171–80.PubMedPubMedCentralCrossRef
189.
190.
Fuziwara CS, Kimura ET. Insights into regulation of the mir-17-92 cluster of miRNAs in cancer. Front Med. 2015;2:64.CrossRef
191.
Ma Y-S, et al. microRNA-320b suppresses HNF4G and IGF2BP2 expression to inhibit angiogenesis and Tumor growth of Lung cancer. Carcinogenesis. 2021;42(5):762–71.PubMedCrossRef
192.
Wang H, et al. ZEB1 induces non-small cell Lung cancer development by targeting microRNA-320a to increase the expression of RAD51AP1. Exp Cell Res. 2021;405(2):112687.PubMedCrossRef
193.
Li ZH, et al. MicroRNA-506 has a suppressive effect on the tumorigenesis of nonsmall-cell Lung cancer by regulating tubby-like protein 3. Bioengineered. 2021;12(2):10176–86.PubMedPubMedCentralCrossRef
194.
Asghariazar V, et al. Tumor suppressor microRNAs in Lung cancer: an insight to signaling pathways and drug resistance. J Cell Biochem. 2019;120(12):19274–89.PubMedCrossRef
195.
Tang Z, et al. Abnormal gene expression regulation mechanism of myeloid Cell Nuclear differentiation Antigen in Lung Adenocarcinoma. Biology. 2022;11(7):1047.PubMedPubMedCentralCrossRef
196.
Chen Y, Gao D-Y, Huang L. Vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128–41.PubMedCrossRef
197.
Dhuri K, et al. Simultaneous targeting of multiple oncomiRs with phosphorothioate or PNA-based anti-mirs in Lymphoma cell lines. Pharm Res. 2022;39(11):2709–20.PubMedPubMedCentralCrossRef
198.
Weidle UH, Birzele F, Nopora A. MicroRNAs as potential targets for therapeutic intervention with Metastasis of non-small cell Lung cancer. Cancer Genomics Proteomics. 2019;16(2):99–119.PubMedPubMedCentralCrossRef
199.
Kim KC et al. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. Theranostics. 2018;8(16):p. 4409.
200.
Trang P, et al. Systemic delivery of Tumor suppressor microRNA mimics using a Neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011;19(6):1116–22.PubMedPubMedCentralCrossRef
201.
Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discovery. 2013;12(11):847.PubMedCrossRef
202.
Sun Y, et al. Efficient delivery of Echinococcus Multilocularis miRNAs using chitosan nanoparticles. Biomed Pharmacother. 2022;150:112945.PubMedCrossRef
203.
Chaudhary S, et al. Strategic targeting of non-small‐cell Lung cancer utilizing genetic material‐based delivery platforms of nanotechnology. J Biochem Mol Toxicol. 2021;35(7):e22784.PubMedCrossRef
204.
205.
Lee SWL, et al. MicroRNA delivery through nanoparticles. J Controlled Release. 2019;313:80–95.CrossRef
206.
Asakiya C, et al. Current progress of miRNA-derivative nucleotide Drugs: modifications, delivery systems, applications. Expert Opin Drug Deliv. 2022;19(4):435–50.PubMedCrossRef
207.
Yasamineh S, et al. An overview on nanoparticle-based strategies to fight viral Infections with a focus on COVID-19. J Nanobiotechnol. 2022;20(1):440.CrossRef
208.
Yasamineh S, et al. Future prospects of natural polymer-based drug Delivery systems in combating Lung Diseases, in natural polymeric materials based Drug Delivery systems in Lung Diseases. Springer; 2023. pp. 465–82.
209.
Assefi M et al. A state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system. J Drug Deliv Sci Technol, 2023: p. 104623.
210.
Salari Sedigh S, et al. The role of bismuth nanoparticles in the inhibition of bacterial Infection. World J Microbiol Biotechnol. 2023;39(7):1–18.CrossRef
211.
Saadh MJ et al. Progress and prospects on vaccine development against Monkeypox Infection Microbial Pathogenesis, 2023: p. 106156.
212.
213.
Yan Y et al. Non-viral vectors for RNA delivery. J Controlled Release, 2022.
214.
215.
Turcheniuk K, et al. Highly effective photodynamic inactivation of E. Coli using gold nanorods/SiO 2 core–shell nanostructures with embedded verteporfin. Chem Commun. 2015;51(91):16365–8.CrossRef
216.
217.
Muthiah M, Park IK, Cho CS. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics. Expert Opin Drug Deliv. 2013;10(9):1259–73.PubMedCrossRef
218.
Volpini L, et al. Advances in RNA cancer therapeutics: New insight into exosomes as miRNA delivery. Aspects of Molecular Medicine; 2023. p. 100005.
219.
Oveili E, et al. The potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different Diseases. Cell Communication and Signaling. 2023;21(1):1–26.CrossRef
220.
Gholizadeh O, et al. Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. Virol J. 2022;19(1):1–22.CrossRef
221.
Yoo BH, et al. 2’-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res. 2004;32(6):2008–16.PubMedPubMedCentralCrossRef
222.
Yang Z et al. CSB affected on the sensitivity of lung cancer cells to platinum-based drugs through the global decrease of let-7 and miR-29 BMc cancer, 2019. 19: p. 1–13.
223.
224.
Adams BD, Parsons C, Slack FJ. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets. 2016;20(6):737–53.PubMedCrossRef
225.
Li H, et al. miR-1254 promotes Lung cancer cell proliferation by targeting SFRP1. Biomed Pharmacother. 2017;92:913–8.PubMedCrossRef
226.
Wu Y et al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for Lung cancer. Mol Therapy-Nucleic Acids, 2013. 2.
227.
228.
Li S, et al. Overexpression of microRNA125a3p effectively inhibits the cell growth and invasion of Lung cancer cells by regulating the mouse double minute 2 homolog/p53 signaling pathway. Mol Med Rep. 2015;12(4):5482–6.PubMedCrossRef
229.
230.
Murugan D, Rangasamy L. A perspective to weaponize microRNAs against Lung cancer. Non-coding RNA Research. 2023;8(1):18–32.PubMedCrossRef
231.
Yin X, et al. Small cell Lung cancer transformation: from pathogenesis to treatment. In seminars in Cancer Biology. Elsevier; 2022.
232.
Lin EH, et al. Targeting cancer stemness mediated by BMI1 and MCL1 for non-small cell Lung cancer treatment. Journal of Cellular and Molecular Medicine; 2022.
233.
de Hoyos A, DeCamp MM. Surgery for small cell Lung cancer. Torac Surg Clin. 2014;24(4):399–409.
234.
Passaro A, et al. Managing resistance to immune checkpoint inhibitors in Lung cancer: treatment and novel strategies. J Clin Oncol. 2022;40(6):598–610.PubMedCrossRef
235.
Mathieu L, et al. FDA approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-based chemotherapy in extensive stage small cell Lung Cancer. Oncologist. 2021;26(5):433–8.PubMedPubMedCentralCrossRef
236.
Yuwen D, et al. Prognostic role of circulating exosomal mir-425-3p for the response of NSCLC to platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev. 2019;28(1):163–73.PubMedCrossRef
237.
Zhou C, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell Lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol. 2022;23(2):220–33.PubMedCrossRef
238.
Wang X, et al. Platinum (IV) Prodrugs with Cancer Stem Cell Inhibitory effects on Lung Cancer for Overcoming Drug Resistance. Journal of Medicinal Chemistry; 2022.
239.
Lampis A, et al. MicroRNAs as mediators of drug resistance mechanisms. Curr Opin Pharmacol. 2020;54:44–50.PubMedCrossRef
240.
Shahverdi M, et al. The regulatory role of autophagy-related miRNAs in Lung cancer drug resistance. Biomed Pharmacother. 2022;148:112735.PubMedCrossRef
241.
Zhang Q, et al. Construction of a dual-functional dumbbell probe-based fluorescent biosensor for cascade amplification detection of miRNAs in Lung cancer cells and tissues. Chem Commun. 2022;58(36):5538–41.CrossRef
242.
Lai J, et al. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell Lung cancer. BMC Cancer. 2019;19(1):1–9.CrossRef
243.
Xia M, et al. MiR-194-5p enhances the sensitivity of nonsmall-cell Lung cancer to doxorubicin through targeted inhibition of hypoxia-inducible factor-1. World J Surg Oncol. 2021;19(1):1–8.CrossRef
244.
Li K, Zhu X, Yuan C. Inhibition of mir-185-3p confers erlotinib resistance through upregulation of PFKL/MET in Lung Cancers. Front Cell Dev Biology, 2021: p. 1863.
245.
Li Q, Wang Y, He J. MiR-133a‐3p attenuates resistance of non‐small cell Lung cancer cells to gefitinib by targeting SPAG5. J Clin Lab Anal. 2021;35(7):e23853.PubMedPubMedCentralCrossRef
246.
Du H, et al. miR–139–5p enhances cisplatin sensitivity in non–small cell Lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of homeobox protein Hox–B2. Mol Med Rep. 2021;23(2):1–1.
247.
Liu H-N, et al. miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell Lung cancer cells by targeting Bcl-2. Archives of Medical Science. 2018;14(4):745–51.PubMedPubMedCentral
248.
Yang X, et al. Intensified beclin-1 mediated by low expression of mir-30a-5p promotes chemoresistance in human small cell Lung cancer. Cell Physiol Biochem. 2017;43(3):1126–39.PubMedCrossRef
249.
Ranade AR, et al. MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell Lung cancer. J Thorac Oncol. 2010;5(8):1273–8.PubMedCrossRef
250.
Tan Q et al. Circular RNA circ_0000517 facilitates the growth and metastasis of non-small cell lung cancer by sponging miR-326/miR-330-5p Cell Journal (Yakhteh), 2021. 23(5): p. 552.
251.
Li X, et al. Hsa_circ_0020850 promotes the malignant behaviors of lung adenocarcinoma by regulating miR-326/BECN1 axis. World J Surg Oncol. 2022;20(1):1–14.
252.
El-Husseiny AA, et al. miRNAs orchestration of salivary gland cancer-Particular emphasis on diagnosis, progression, and drug resistance. Pathology-Research and Practice. 2023;248:154590.PubMedCrossRef
253.
254.
Bahrami A et al. The prognostic and therapeutic application of microRNAs in Breast cancer: tissue and circulating microRNAs. 2018. 233(2): p. 774–86.
255.
He Y, et al. Current state of circulating MicroRNAs as Cancer biomarkers. Clin Chem. 2015;61(9):1138–55.PubMedCrossRef
256.
Huang YK, Yu JC. Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: an update and review. World J Gastroenterol. 2015;21(34):9863–86.PubMedPubMedCentralCrossRef
257.
258.
Zhang H, et al. Plasma miR–145, miR–20a, miR–21 and miR–223 as novel biomarkers for screening early–stage non–small cell Lung cancer. Oncol Lett. 2017;13(2):669–76.PubMedCrossRef
259.
Zhu W, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell Lung cancer. PLoS ONE. 2016;11(4):e0153046.PubMedPubMedCentralCrossRef
260.
Powrózek T, et al. The diagnostic role of plasma circulating precursors of miRNA-944 and miRNA-3662 for non-small cell Lung cancer detection. Pathology-Research and Practice. 2017;213(11):1384–7.PubMedCrossRef
261.
Sromek M, et al. Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell Lung cancer resection. Cell Oncol. 2017;40(5):529–36.CrossRef
262.
Ge X, et al. MicroRNA-106a-5p alleviated the resistance of cisplatin in Lung cancer cells by targeting Jumonji domain containing 6. Transpl Immunol. 2021;69:101478.PubMedCrossRef
263.
Wang H, et al. Cancer-released exosomal circular RNA circ_0008717 promotes cell tumorigenicity through microRNA-1287-5p/P21-activated kinase 2 (PAK2) axis in non-small cell Lung cancer. Bioengineered. 2022;13(4):8937–49.PubMedPubMedCentralCrossRef
264.
El-Daly SM, Gouhar SA, Abd Elmageed ZY. Circulating microRNAs as reliable Tumor biomarkers: opportunities and challenges facing clinical application. J Pharmacol Exp Ther. 2023;384(1):35–51.PubMedCrossRef
265.
Uso M, et al. miRNA detection methods and clinical implications in Lung cancer. Future Oncol. 2014;10(14):2279–92.PubMedCrossRef
266.
Chen H et al. Modified exosomes: a good transporter for miRNAs within stem cells to treat Ischemic Heart Disease. J Cardiovasc Transl Res, 2022: p. 1–10.
267.
Zhang Y, et al. Inflammasome-derived exosomes activate NF-κB signaling in macrophages. J Proteome Res. 2016;16(1):170–8.PubMedCrossRef
268.
Li C, et al. The role of Exosomal miRNAs in cancer. J Translational Med. 2022;20(1):1–15.CrossRef
269.
Yasamineh S, et al. Spotlight on therapeutic efficiency of mesenchymal stem cells in viral Infections with a focus on COVID-19. Stem Cell Res Ther. 2022;13(1):1–23.CrossRef
270.
Bouzari B, et al. Angioregulatory role of miRNAs and exosomal miRNAs in glioblastoma pathogenesis. Biomed Pharmacother. 2022;148:112760.PubMedCrossRef
271.
Paskeh MDA, et al. Emerging role of exosomes in cancer progression and Tumor microenvironment remodeling. J Hematol Oncol. 2022;15(1):1–39.CrossRef
272.
Fabbri M et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response Proceedings of the National Academy of Sciences, 2012. 109(31): p. E2110-E2116.
273.
Rabinowits G, et al. Exosomal microRNA: a diagnostic marker for Lung cancer. Clin Lung Cancer. 2009;10(1):42–6.PubMedCrossRef
274.
Kidd ME, Shumaker DK, Ridge KM. The role of vimentin intermediate filaments in the progression of Lung cancer. Am J Respir Cell Mol Biol. 2014;50(1):1–6.PubMedPubMedCentralCrossRef
275.
Kadota T, et al. Extracellular vesicles in Lung cancer—from bench to bedside. In seminars in cell & developmental biology. Elsevier; 2017.
276.
Dejima H, et al. Exosomal microRNA in plasma as a non–invasive biomarker for the recurrence of non–small cell Lung cancer. Oncol Lett. 2017;13(3):1256–63.PubMedPubMedCentralCrossRef
277.
278.
Cazzoli R, et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing Lung cancer. J Thorac Oncol. 2013;8(9):1156–62.PubMedPubMedCentralCrossRef
279.
Florczuk M, Szpechcinski A, Chorostowska-Wynimko J. miRNAs as biomarkers and therapeutic targets in non-small cell Lung cancer: current perspectives. Target Oncol. 2017;12(2):179–200.PubMedCrossRef
280.
Gao F, et al. Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. Oncol Rep. 2014;31(1):351–7.PubMedCrossRef
281.
Zhou Y et al. Exosomal transfer of mir-195-5p restrains lung adenocarcinoma progression. Exp Cell Res, 2023: p. 113485.
282.
Lin J et al. Exosomes: novel biomarkers for clinical diagnosis ScientificWorldJournal, 2015. 2015: p. 657086.
283.
Schwarzenbach H. The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn. 2015;15(9):1159–69.PubMedCrossRef
284.
Gusachenko O, Zenkova M, Vlassov V. Nucleic acids in exosomes: Disease markers and intercellular communication molecules. Biochem (Moscow). 2013;78(1):1–7.CrossRef
285.
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.PubMedCrossRef
286.
Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and Disease. Vet Pathol. 2014;51(4):759–74.PubMedCrossRef
287.
Finnegan EF, Pasquinelli AE. MicroRNA biogenesis: regulating the regulators. Crit Rev Biochem Mol Biol. 2013;48(1):51–68.PubMedCrossRef
288.
Zhu Y, et al. Identification of potential circular RNA biomarkers in lung adenocarcinoma: a bioinformatics analysis and retrospective clinical study. Oncol Lett. 2022;23(5):1–13.CrossRef
289.
Tang S, et al. MicroRNAs: emerging oncogenic and tumor-suppressive regulators, biomarkers and therapeutic targets in Lung cancer. Cancer Lett. 2021;502:71–83.PubMedCrossRef
290.
Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discovery. 2014;13(8):622.PubMedCrossRef
291.
292.
293.
Gerber DE et al. Randomized Phase 2 Study of Tivantinib plus Erlotinib versus Single-agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-small Cell Lung Cancer Lung Cancer, 2018.
294.
295.
Usó M, et al. miRNA detection methods and clinical implications in Lung cancer. Future Oncol. 2014;10(14):2279–92.PubMedCrossRef
296.
297.
Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age EMBO molecular medicine, 2014: p. e201100899.
298.
299.
van Zandwijk N et al. P1: 02 MESOMIR 1: A PHASE I STUDY OF TARGOMIRS IN PATIENTS WITH REFRACTORY MALIGNANT PLEURAL MESOTHELIOMA (MPM) AND LUNG CANCER (NSCLC). Ann Oncol, 2015. 26.
300.
St Clair EW. Targeted EDV™ Nanocells carrying small interfering RNA (siRNA) molecules to overcome drug resistance in Non-small cell lung cancer. 2021.
301.
Reid G, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics. 2016;8(8):1079–85.PubMedCrossRef
302.
Deb D, Moore AC, Roy UB. The 2021 global Lung cancer therapy landscape. J Thorac Oncol. 2022;17(7):931–6.PubMedCrossRef
303.
Tan AC, Tan DS. Targeted therapies for Lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–25.PubMedCrossRef
304.
Liang X, et al. MicroRNAs as early diagnostic biomarkers for non–small cell Lung cancer. Oncol Rep. 2023;49(1):1–12.
305.
Murugan D, Rangasamy L. A perspective to weaponize microRNAs against Lung cancer. Non-coding RNA Research; 2022.
306.
Yan H, et al. MiRNAs in anti-cancer drug resistance of non-small cell Lung cancer: recent advances and future potential. Front Pharmacol. 2022;13:949566.PubMedPubMedCentralCrossRef
307.
308.
Han Y, Li H. miRNAs as biomarkers and for the early detection of non-small cell Lung cancer (NSCLC). J Thorac Disease. 2018;10(5):3119.CrossRef
309.
Wang W, et al. MicroRNA-21 as a diagnostic and prognostic biomarker of Lung cancer: a systematic review and meta-analysis. Biosci Rep. 2022;42(5):BSR20211653.PubMedPubMedCentralCrossRef
310.
Chen C, et al. Early detection of Lung cancer via biointerference-free, target microRNA-triggered core–satellite nanocomposites. Nanoscale. 2022;14(22):8103–11.PubMedCrossRef
Metadata
Title
Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review
Authors
Mohammad Saleh Sadeghi
Mohadeseh lotfi
Narges Soltani
Elahe Farmani
Jaime Humberto Ortiz Fernandez
Sheida Akhlaghitehrani
Safaa Hallol Mohammed
Saman Yasamineh
Hesam Ghafouri Kalajahi
Omid Gholizadeh
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03133-z

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Research

FOXA1/MND1/TKT axis regulates gastric cancer progression and oxaliplatin sensitivity via PI3K/AKT signaling pathway

Research

Exosomal circRNA RHOT1 promotes breast cancer progression by targeting miR-204-5p/ PRMT5 axis

Review

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Research

SIAH1 ubiquitination-modified HMGCR inhibits lung cancer progression and promotes drug sensitivity through cholesterol synthesis

Research

Interplay between lncRNA RP11-367G18.1 variant 2 and YY1 plays a vital role in hypoxia-mediated gene expression and tumorigenesis

Research

Therapeutic effect and transcriptome-methylome characteristics of METTL3 inhibition in liver hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits